ES2196898T3 - Antagonistas de receptores de crf y metodos relacionados. - Google Patents

Antagonistas de receptores de crf y metodos relacionados.

Info

Publication number
ES2196898T3
ES2196898T3 ES99961675T ES99961675T ES2196898T3 ES 2196898 T3 ES2196898 T3 ES 2196898T3 ES 99961675 T ES99961675 T ES 99961675T ES 99961675 T ES99961675 T ES 99961675T ES 2196898 T3 ES2196898 T3 ES 2196898T3
Authority
ES
Spain
Prior art keywords
crf receptor
receptor antagonists
crf
antagonists
receivers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99961675T
Other languages
English (en)
Spanish (es)
Inventor
Mustapha Haddach
Zhiqiang Guo
James R Mccarthy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurocrine Biosciences Inc
Original Assignee
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc
Application granted granted Critical
Publication of ES2196898T3 publication Critical patent/ES2196898T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/16—Peri-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ES99961675T 1998-11-12 1999-11-12 Antagonistas de receptores de crf y metodos relacionados. Expired - Lifetime ES2196898T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19095898A 1998-11-12 1998-11-12
US40074499A 1999-09-21 1999-09-21

Publications (1)

Publication Number Publication Date
ES2196898T3 true ES2196898T3 (es) 2003-12-16

Family

ID=26886600

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99961675T Expired - Lifetime ES2196898T3 (es) 1998-11-12 1999-11-12 Antagonistas de receptores de crf y metodos relacionados.

Country Status (19)

Country Link
US (3) US6348466B1 (OSRAM)
EP (1) EP1129096B1 (OSRAM)
JP (1) JP2002529469A (OSRAM)
KR (1) KR20010080402A (OSRAM)
CN (1) CN1178941C (OSRAM)
AT (1) ATE240958T1 (OSRAM)
AU (1) AU755997B2 (OSRAM)
BR (1) BR9915129A (OSRAM)
CA (1) CA2349904A1 (OSRAM)
DE (1) DE69908173T2 (OSRAM)
DK (1) DK1129096T3 (OSRAM)
ES (1) ES2196898T3 (OSRAM)
HK (1) HK1038925B (OSRAM)
IL (1) IL143105A0 (OSRAM)
NO (1) NO20012228D0 (OSRAM)
NZ (1) NZ511267A (OSRAM)
PT (1) PT1129096E (OSRAM)
TR (1) TR200102178T2 (OSRAM)
WO (1) WO2000027850A2 (OSRAM)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030016222A (ko) * 2000-02-14 2003-02-26 니뽄 다바코 산교 가부시키가이샤 수술후 스트레스 예방ㆍ치료제
WO2001083486A1 (en) * 2000-05-01 2001-11-08 Bristol-Myers Squibb Pharma Company Tricyclic fused pyridine and pyrimidine derivatives as crf receptor antagonists
WO2001087889A1 (en) * 2000-05-18 2001-11-22 Neurocrine Biosciences, Inc. Crf receptor antagonists and methods relating thereto
JP2003533526A (ja) * 2000-05-18 2003-11-11 ニューロクライン バイオサイエンシーズ， インコーポレイテッド Ｃｒｆレセプターアンタゴニストおよびそれに関連する方法
DE60126134T2 (de) * 2000-11-03 2007-10-18 Neurocrine Biosciences, Inc., San Diego CRF-Rezeptorantagonisten und Verfahren, die damit in Beziehung stehen
JP2004518731A (ja) * 2000-12-28 2004-06-24 ニューロクライン バイオサイエンシーズ， インコーポレイテッド 三環式ｃｒｆレセプターアンタゴニスト
ES2294047T3 (es) 2000-12-28 2008-04-01 Ono Pharmaceutical Co., Ltd. Un compuesto de ciclopenta (d) pirazolo(1,5-a) pirimidina como antagonista del receptor de crf.
AU2002249474B2 (en) 2001-04-30 2006-01-12 Glaxo Group Limited Crf receptor antagonists
GB0117395D0 (en) * 2001-07-17 2001-09-05 Glaxo Group Ltd Chemical compounds
US7273871B2 (en) 2001-07-17 2007-09-25 Sb Pharmco Puerto Rico Inc. Phenyl-5,6,6A,7,8,9-hexahydro-4H-1,4,9-triaza-phenalene derivatives as CRF antagonists
ATE478873T1 (de) 2003-06-25 2010-09-15 Ono Pharmaceutical Co Methansulfonsäuresalz einer pyrazolopyrimidinverbindung, kristall davon und verfahren zu deren herstellung
US20060024661A1 (en) * 2003-07-30 2006-02-02 The Regents Of The University Of California Modulation of CRF potentiation of NMDA receptor currents via CRF receptor 2
DE602004012318T2 (de) * 2003-12-22 2009-03-12 Sb Pharmco Puerto Rico Inc. Crf-rezeptorantagonisten und diese betreffende verfahren
CN102453763A (zh) 2004-06-03 2012-05-16 阿什洛米克斯控股有限公司 诊断应激的药物和方法
CA2576435A1 (en) * 2004-08-09 2006-03-23 Research Development Foundation Determination of the 3d-structure of an extracellular domain of a b1 g-protein coupled receptor by nmr analysis
WO2007050087A1 (en) 2004-08-25 2007-05-03 Ardea Biosciences, Inc. N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS
WO2006026356A2 (en) 2004-08-25 2006-03-09 Ardea Biosciences, Inc. S-TRIAZOLYL α-MERCAPTOACETANILDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE
US8227601B2 (en) 2005-05-05 2012-07-24 Ardea Biosciences, Inc. Diaryl-purines, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitor for treatment of HIV
US7595324B2 (en) 2006-11-09 2009-09-29 Ardea Biosciences, Inc. Substituted thieno[3,2-D]pyrimidines as HIV inhibitors
BRPI0819847B1 (pt) 2007-11-27 2022-01-11 Ardea Biosciences, Inc Compostos e composições
WO2009079412A2 (en) 2007-12-14 2009-06-25 Ardea Biosciences Inc. Reverse transcriptase inhibitors

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4605642A (en) 1984-02-23 1986-08-12 The Salk Institute For Biological Studies CRF antagonists
US5013737A (en) * 1988-02-22 1991-05-07 American Cyanamid Company 2,4,8-Trisubstituted-3H,6H-1,4,5A,8A-tetraazaacenaphtylene-3,5-(4H)-diones and 2,4-8-trisubstituted-4,5-dihydro-5-thioxo-3H,6H-1,4,5A,8A-tetrazaacenaphthylen-3-ones
US4904658A (en) 1988-04-15 1990-02-27 American Cyanamid Company Substituted-6H,8H-pyrimido-[1,2,3-cd]purine-8,10-(9H)-diones and substituted-6H,10H-pyrimido[1,2-cd]purin-10-ones
US5063245A (en) 1990-03-28 1991-11-05 Nova Pharmaceutical Corporation Corticotropin-releasing factor antagonism compounds
FR2692893B1 (fr) 1992-06-24 1994-09-02 Sanofi Elf Dérivés alkylamino ramifiés du thiazole, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent.
CA2150703C (en) 1992-12-17 2002-01-08 Pfizer Limited Substituted pyrazoles
TW336932B (en) 1992-12-17 1998-07-21 Pfizer Amino-substituted pyrazoles
TW444018B (en) 1992-12-17 2001-07-01 Pfizer Pyrazolopyrimidines
US5712303A (en) 1992-12-17 1998-01-27 Pfizer Inc. Pyrazoles and pyrazolopyrimidines having CRF antagonistic activity
ES2128544T3 (es) 1992-12-17 1999-05-16 Pfizer Pirrolopirimidinas como antagonistas del crf.
JP3398152B2 (ja) 1993-10-12 2003-04-21 ブリストル‐マイヤーズ・スクイブ・ファーマ・カンパニー １ｎ−アルキル−ｎ−アリールピリミジンアミンおよびその誘導体
TW574214B (en) 1994-06-08 2004-02-01 Pfizer Corticotropin releasing factor antagonists
EP0765327B1 (en) 1994-06-16 1999-07-21 Pfizer Inc. Pyrazolo and pyrrolopyridines
JPH10506126A (ja) 1995-05-12 1998-06-16 ニューロゲン コーポレイション 新規なデアザプリン誘導体；ｃｒｆ１特異性リガンドの新規なクラス
FR2735777B1 (fr) 1995-06-21 1997-09-12 Sanofi Sa Derives de 4-phenylaminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
EP0901476A4 (en) 1996-03-26 2001-08-16 Du Pont Pharm Co PYRIDINES AND PYRIMIDINES FUSION ARYLOXY AND ARYLTHIO AND DERIVATIVES THEREOF
US6326368B1 (en) 1996-03-27 2001-12-04 Dupont Pharmaceuticals Company Aryloxy- and arylthiosubstituted pyrimidines and triazines and derivatives thereof
US6107300A (en) 1996-03-27 2000-08-22 Dupont Pharmaceuticals Arylamino fused pyrimidines
ZA973884B (en) * 1996-05-23 1998-11-06 Du Pont Merck Pharma Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders
HU229024B1 (en) 1996-07-24 2013-07-29 Bristol Myers Squibb Pharma Co Azolo-pyridimidines, pharmaceutical compositions containing the same and use thereof
NZ333727A (en) 1996-08-06 2000-09-29 Pfizer Substituted pyrido- or pyrimido-containing 6,6- or 6,7-bicyclic arylsulfonylamino hydroxamic acid derivatives
TW477787B (en) 1996-08-27 2002-03-01 Pfizer Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same
TR199900389T2 (xx) * 1996-08-28 2000-06-21 Pfizer Inc. �kame edilmi� 6,5-hetero-bisiklik t�revleri.
DE69710594T2 (de) 1996-09-16 2002-08-29 Du Pont Pharmaceuticals Co., Wilmington Eine resorbierbare röntgenopake markierung enthaltendes chirurgisches implantat und verfahren zum verriegeln desselben in einem körper
FR2754258B1 (fr) 1996-10-08 1998-12-31 Sanofi Sa Derives d'aminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
US5760225A (en) 1996-11-15 1998-06-02 Neurogen Corporation Certain pyrazole derivatives as corticotropin-releasing factor receptor CRF1 specific ligands
US5723608A (en) 1996-12-31 1998-03-03 Neurogen Corporation 3-aryl substituted pyrazolo 4,3-d!pyrimidine derivatives; corticotropin-releasing factor receptor (CRF1) specific ligands

Also Published As

Publication number Publication date
WO2000027850A2 (en) 2000-05-18
EP1129096B1 (en) 2003-05-21
DE69908173T2 (de) 2004-08-19
AU755997B2 (en) 2003-01-02
HK1038925A1 (en) 2002-04-04
DE69908173D1 (de) 2003-06-26
US6348466B1 (en) 2002-02-19
IL143105A0 (en) 2002-04-21
NO20012228L (no) 2001-05-04
JP2002529469A (ja) 2002-09-10
CA2349904A1 (en) 2000-05-18
PT1129096E (pt) 2003-09-30
TR200102178T2 (tr) 2002-01-21
BR9915129A (pt) 2001-08-07
NZ511267A (en) 2002-12-20
EP1129096A2 (en) 2001-09-05
CN1178941C (zh) 2004-12-08
WO2000027850A3 (en) 2000-08-03
ATE240958T1 (de) 2003-06-15
KR20010080402A (ko) 2001-08-22
NO20012228D0 (no) 2001-05-04
AU1819900A (en) 2000-05-29
US20040229879A1 (en) 2004-11-18
US20020143008A1 (en) 2002-10-03
US6723721B2 (en) 2004-04-20
HK1038925B (en) 2003-12-05
DK1129096T3 (da) 2003-09-15
CN1326458A (zh) 2001-12-12

Similar Documents

Publication Publication Date Title
BR9911621A (pt) Bifenil sulfonamidas como antagonista duplos de receptor de angiotensina endotelina
DE60231911D1 (de) Sedierende und nicht sedierende antihistamine enthaltende zusammensetzungen
ES2150489T3 (es) 1-amidinofenil-pirrolidonas, -piperidinonas, -azetinonas como inhibidores de la agregacion de plaquetas.
PT1326643E (pt) Inibicao do efeito emetico da metformina com antagonistas de receptores 5-ht3
AR002268A1 (es) Antagonistas de vasopresina de benzacepina triciclicos, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso dedichos compuestos para preparar composiciones farmaceuticas.
ES2161291T3 (es) N-(indol-2-carbonil)amidas y derivados como inhibidores de la glucogeno fosforilasa.
EA199800563A1 (ru) Антагонисты гормона, высвобождающего гонадотропин
AR011134A1 (es) Derivados de imidazo piridina substituidos para la inhibicion de la secrecion de acido gastrico; una sal del mismo, procedimiento para su preparacion, formulacion farmaceutica que los contiene y el uso de dicho compuesto para la manufactura de un medicamento
UY26130A1 (es) Compuestos para tratar la obesidad
FR2838439B1 (fr) Derives de terphenyle, leur preparation, les compositions pharmaceutqiues en contenant
EA200200571A1 (ru) Новая композиция и ее применение
PL356252A1 (en) Synergistic combination of pde inhibitors and beta 2 adrenoceptor agonist
PA8486001A1 (es) Composiciones de celecoxib
BRPI0410563A (pt) derivados de pirazol-quinazolina processo para sua preparação e seu uso como inibidores de quinase
EA200700118A1 (ru) Амидосоединения и их применение в качестве лекарственных средств
AR029605A1 (es) DERIVADOS DE DIFENILUREA SUBSTITUIDOS CON SULFONAMIDA , COMPOSICIoN FARMACEUTICA , USO DE LOS MISMOS PARA LA MANUFACTURA DE UN MEDICAMENTO uTILES COMO ANTAGONISTA DE RECEPTORES DE IL-8, COMPUESTOS, INTERMEDIARIOS, Y MÉTODOS DE CONVERSIoN DE COMPUESTOS
BRPI0411155A (pt) composto que se liga a e ativa o receptor de eritropoietina, composição farmacêutica e seu uso
MXPA03008756A (es) Derivados de n-(arilsulfonil) beta-aminoacidos que comprenden un grupo aminometilo substituido, el metodo de preparacion de los mismos y las composiciones farmaceuticas que los contienen.
BR9910144A (pt) Antagonistas de receptores de quimiocinas e seu uso
TR199900326T2 (xx) �st solunum yollar� alerjik tepkisinin histamin resept�r antagonistlerin bir birle�imi ile tedavisi.
CL2004000590A1 (es) Compuestos derivados de 1,3,4-oxadiazol-3-ona, 1,3,4-tiadiazol-2-ona y de 1,2,4-triazol-3-ona; composicion farmaceutica que los contiene; procedimiento de preparacion y su uso en la preparacion de un medicamento en los que esta relacionado el virus v
HUP0103203A2 (hu) Azaadamantánszármazékok és ezeket tartalmazó gyógyszerkészítmények
ES2095662T3 (es) Derivados de imidazol con actividad antagonista de la angiotensina ii.
SE0102055D0 (sv) New Compounds
NO20014855D0 (no) N-(2-fenyl-4-aminobutyl)-1-naftamider som neurokinin-1- reseptorantagonister